Eurofins Scientific

Eurofins Scientific is an international life sciences company operating in food & pharmaceutical products testings. Co. provides analytical testing services to clients from various industries including pharmaceutical, food, and environmental sectors. Co. offers analytical methods for evaluating the authenticity, origin, safety, identity, composition, and purity of biological substances & products. Co. verifies authenticity of products analyzed to detect dangerous components (pathogens, prions, pesticides, asbestos, mycotoxins, dioxins, toxic substances, etc.). Co. operates in Benelux, France, Germany, North America, Scandinavia, British Isles (U.K. & Republic of Ireland), & other countries.
  • TickerERF
  • ISINFR0000038259
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Eurofins Scientific: 1 director sold

A director at Eurofins Scientific sold 100 shares at 585.000EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Dave Nicoski ...
  • Ross LaDuke

Int'l Insights: Bullish Developed Markets Stocks

Overweight Global Technology & Industrials The absence of breakdowns in both the US dollar (DXY) and the MSCI EAFE vs. EM ratio along with the positive correlation between the two allows us to continue sticking with EAFE over EM... see charts below. As long as the DXY's uptrend remains intact, we expect EAFE to continue outperforming EM. Below we highlight attractive and actionable themes within developed int'l markets: • Technology and Industrial Manufacturing. Technology and Industrials continue to be two of the most attractive Sectors globally -- overweight. These two Sectors account fo...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care Hitting On All Cylinders Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout... see chart below. • Market Ignoring Negative Headlines. Global equity markets continue to generally shrug off seemingly bearish headlines surrounding trade, Trump impeachment hearings, and ongoing protests in Hong Kong. This tells us that the good outweighs the bad in the eyes of the market. While we view the fact that none of these issues have yet to derail global m...

Jérôme VINERIER

Analyse court terme - EUROFINS SCIENTIFIC : La reprise est une consolidation.

La tendance est baissière. La reprise est une consolidation. Les Stochastiques sont en zone de surachat. La baisse peut bientôt reprendre vers 399,00 €. La tendance de fond serait remise en cause en cas de franchissement de 492,30 €.

Jérôme VINERIER

Short term view - EUROFINS SCIENTIFIC : The recovery is a consolidation.

The trend is bearish. The recovery is a consolidation. Stochastics are at the overbought level. The fall can soon resume toward €399.00. The background trend would be questioned should prices rise above €492.30.

Jérôme VINERIER

Short term view - EUROFINS SCIENTIFIC : The trend is bearish.

The trend is bearish. The recovery is a consolidation. The fall might resume toward €399.00. The background trend would be questioned should prices rise above €492.30.

Eurofins Scientific: 1 director sold

A director at Eurofins Scientific sold 100 shares at 585.000EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : Orders for tests linked to COVID-19 appear to be lower than the ramp-up of production capacity

>At end-May, the option that represented the COVID-19 tests does not appear so significant - At the time of Eurofins' capital increase (mid-May 2020), we reiterated that the option represented by the sales of COVID-2019 tests was to be put in the conditional, as it implied i/ an increase in production capacity (on which Eurofins is in line and ii/ a ramp-up of demand for tests.A few weeks later, after analysis of data on the ramp-up of tests in a number of countr...

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : Les commandes de tests liés au COVID-19 semblent inférieures à la montée en puissance des capacités de production

>A fin mai, l’option que représentaient les tests liés au COVID-19 semble ne pas être si importante que cela - A l’occasion de l’augmentation de capital d’Eurofins (mi-mai 2020), nous avions rappelé que l’option que représentaient les ventes de tests liés au COVID 2019 étaient à mettre au conditionnel, car elle impliquait une montée en puissance i/ des capacités de production (sur laquelle Eurofins est en ligne) et ii/ de la demande de tests.Quelques semaines plu...

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : Capital increase of around € 500m via an ABB, at the right time in our view – Buy vs Neutral and target price raised to € 600 (vs € 500)

>Issuance of around 900,000 shares, for some € 500m - Yesterday evening after the close, Eurofins announced it was launching a capital increase through an accelerated book building (ABB) process, for around 900,000 new shares, i.e. around 5% in additional shares (17.9m shares before the capital increase ).The stated aims of this transaction are to: i/ finance capex and working capital related to tests (PCR, antibody, and other) for COVID-19, and ii/ be able to se...

Christophe-Raphaël Ganet ...
  • Geoffroy Michalet

Eurofins : Augmentation de capital d’environ 500 M€ par ABB, au bon moment selon nous – Achat vs Neutre et OC à 600 € (vs 500 €)

>Emission d’environ 900 000 actions, pour 500 M€ environ - Hier soir après clôture, Eurofins a annoncé une augmentation de capital via un Accelerated Book Building (ABB), pour environ 900 000 actions nouvelles, soit environ 5% d’actions supplémentaires (17.9 M d’actions avant AK).Les objectifs annoncés de cette opération sont i/ de financer les investissements et le BFR liés aux tests (PCR, Sérologiques et autre) du COVID-19 et ii/ d’être en mesure de saisir des ...

Christophe-Raphaël Ganet

ODDO : Update

>Resilience confirmed: Q1 sales: +6% - To date, the sector has reported around 6% growth in Q1 revenues (Q2 will be more impacted: -10%e in our models). At the same time, we have lowered, on average, our projections by around 3% on 2020e revenues and by 9% on 2020e OIR.Finally, in the crisis, half of the issuers have, at this stage, cancelled the payment of their dividend.Performances: +14% (over the last 2 months) - At the same time, the sector'...

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 04/03/2020 - Eurofins

TP ICAP (Europe) S.A. | Recherche Crédit | Mercredi 4 mars 2020 Eurofins (Achat) : Table sur un cash-flow libre très solide de plus de €500m en 2020 et 2021 Crédit Mutuel Arkéa (Achat) : RN de €511m (+16,8%) en 2019 Evonik (Achat hybrides) : EBITDA de €2,2 mds (+0,1%) en 2019 Elis (Achat) : BITDA de €1,1 md (+11,9%) en 2019 ESG: OMV (Achat) : Souhaite devenir leader sur la transformation des plastiques en pétrole IGT (Achat) : EBITDA de $1,7 md (+2% en organique) en 2019 Hellenic Petroleum (Conserver versus Achat) : EBITDA de €572m...

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 29/10/2019 - AT&T - EN

AT&T: Plans $5bn To $10bn Of Assets Disposal In 2020 Commerzbank (U/P) -Q3-19: Net Profit of €294m (+34.9%) Mediobanca (O/P) - Q1-19/20: Net Profit of €271m (+10.3%) Bharti Airtel (U/P): Postpones The Publication of Its Half Year Results Orange (Outperform: Hybrids) - 9M-19: EBITDA (After Leases) of €9.6bn (+0.6% LfL) Unibail-Rodamco-Westfield (M/P) - 9M-19: Revenues of €2.2bn (+17.7%) Imerys (O/P) - 9M-19: Current Operating Income of €358m (-15.7%) S&P Affirms RCI Banque's BBB Rating (O/P), the Outlook Remains Negative

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 29/10/2019 - AT&T - FR

AT&T : Prévoit de céder $5 mds à $10mds d’actifs en 2020 Commerzbank (Vente) -T3-19:  RN de €294m (+34,9%) Mediobanca (Achat) - T1-19/20 : RN de €271m (+10,3%) Bharti Airtel (Vente) : Reporte la publication de ses résultats semestriels Orange (Achat hybrides) - 9M-19 : EBITDA (après leases) de €9,6 mds (+0,6% en comparable) Unibail-Rodamco-Westfield (Conserver) – 9M-19 : Revenus de €2,2 mds (+17,7%) Imerys (Achat) - 9M-19 : Résultat opérationnel courant de €358m (-15,7%) S&P confirme la note BBB de RCI Banque (Achat), la perspe...

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 28/10/2019 - Eurofins - EN

TP ICAP - Europe - Morning CreditUpdate 28/10/2019 - Eurofins - EN

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 28/10/2019 - Eurofins - FR

Eurofins (Achat) - T3-19 : Revenus de €1,2md (+22,3%, +6,4% en organique) HSBC (Achat) : Abaisse ses perspectives de revenus pour 2019, l’objectif d’un ROTE >11% en 2020 ne sera pas atteint AXA (Achat) : Cède ses activités bancaires en Belgique à Crelan Banque pour €620m Cemex (Achat) - 9M-19 : EBITDA de $1,9 md (-11%, -9% en organique) Aroundtown  (Conserver) et TLG Immobilien (Achat) : Accord sur les conditions d’une fusion Suedzucker (Vente) : Rehausse son objectif de résultat opérationnel pour l’exercice 2019-2020 Verizon (Achat) - 9M...

Benoit Valleaux ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Geoffroy Michalet
  • Louis Boujard, CFA
  • Martial Descoutures
  • Philippe Ourpatian
  • Roland Pfaender,MBA,CFA,CCRA
  • Sebastien Malafosse
  • Stephane Houri
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/08/2020

Since 2009, the outperformance of growth has been due to investors' determination to protect themselves against sluggish growth and falling interest rates. If we adopt a sequential point of view, these two parameters evolve in favour of value: 1/ by base effect, apparent growth is expected to be strong on the face of it; 2/ the rapid growth of debt and ultimately the inflationary effects of the relocation of value chains may push long rates up. We propose a list of 18 stocks with a Bu...

Benoit Valleaux ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Geoffroy Michalet
  • Louis Boujard, CFA
  • Martial Descoutures
  • Philippe Ourpatian
  • Roland Pfaender,MBA,CFA,CCRA
  • Sebastien Malafosse
  • Stephane Houri
  • Sylvain Goyon, CFA

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 08/06/2020

Depuis 2009, la surperformance de la croissance s’explique par la volonté des investisseurs de se prémunir contre l’atonie de la croissance et la baisse des taux. Si l’on adopte un point de vue séquentiel, ces deux paramètres évoluent en faveur de la value : 1/ par effet de base la croissance apparente est appelée à être forte facialement ; 2/ la croissance rapide de l’endettement et à terme les effets inflationnistes de la relocalisation des chaines de valeur peuvent pousser les taux...

Alain William ...
  • Alexandre Iatrides
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Tegner
  • Sebastien Malafosse
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/19/2020

...

Alain William ...
  • Alexandre Iatrides
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Tegner
  • Sebastien Malafosse
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 19/05/2020

...

EUROFINS SCIENTIFIC AG with less fundamental stars is reduced to Neutral

EUROFINS SCIENTIFIC AG (FR), a company active in the Health Care Providers industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date January 31, 2020, the closing price was EUR 486.00 and its expected value was estimat...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Eurofins Scientific - Assemblée Générale des actionnaires du 26 Juin 2020

RémunérationsIl est proposé, pour la première fois de donner un avis consultatif sur le rapport et la politique de rémunération. Si la communication de la société concernant les rémunérations long-terme est parfaite, concernant le bonus, elle l’est nettement moins. Elle n’est même pas aux standards français ou européens puisque non seulement la société ne communique pas les bonus annuels effectivement attribués au titre de 2019, mais en plus, elle ne communique pas les critères de performance des bonus annuels. Ce manque de transparence n’est pas acceptable pour une société du SBF 120.

Expert Corporate Governance Service (ECGS)

Eurofins Scientific – AGM 30 June 2020

ITEMS 9 and 10: It is proposed, for the first time, to give an advisory opinion on the remuneration report and policy. While the Company's disclosure on long-term remuneration is perfect, its disclosure on bonuses is far less so. It is not even up to French or European standards, since not only does the Company not disclose the annual bonuses actually awarded for 2019, but it also does not disclose the performance criteria for the annual bonuses. This lack of transparency is not acceptable for a SBF 120 Company.  ITEM 1 of the EGM: It is proposed to renew the authorization to increase the capi...

Eurofins - Assemblée générale des actionnaires du 25 avril 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Eurofins Scientific – Proxinvest Corporate Governance Rating ® : D

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Proxy Report - 26/04/2018

Each year the company publishes the amount of the remuneration due to the executive directors but does not publish any information on the remuneration policy. In addition, the company does not submit any resolution that allows shareholders to approve. Therefore, we will recommend opposition of resolution 7 on the discharge for directors, even if this is a mandatory resolution in Luxembourg. The company proposes two resolution on the renewal of directors. We will support Patrizia Luchetta and Fereshteh Pouchantchi as Directors - both of them are free from conflicts of interest (resolutions 9 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch